Addressing Barriers to the Development and Adoption of Rapid Diagnostic Tests in Global Health
Name
Sikes_Addressing barriers.pdf
Size
969.82 KB
Format
Adobe PDF
Checksum (MD5)
0b6a54c855efade0d30a96f5bcad45f3
Author(s)
Miller, Eric Alexander
Sikes, Hadley
Date Issued
June 2015
Journal
Nanobiomedicine
Publisher
InTech
Citation
Miller, Eric, and Hadley D. Sikes. “Addressing Barriers to the Development and Adoption of Rapid Diagnostic Tests in Global Health.” Nanobiomedicine (2015): 1.
Version
Final published version
Abstract
Immunochromatographic rapid diagnostic tests (RDTs) have demonstrated significant potential for use as point-of-care diagnostic tests in resource-limited settings. Most notably, RDTs for malaria have reached an unparalleled level of technological maturity and market penetration, and are now considered an important complement to standard microscopic methods of malaria diagnosis. However, the technical development of RDTs for other infectious diseases, and their uptake within the global health community as a core diagnostic modality, has been hindered by a number of extant challenges. These range from technical and biological issues, such as the need for better affinity agents and biomarkers of disease, to social, infrastructural, regulatory and economic barriers, which have all served to slow their adoption and diminish their impact. In order for the immunochromatographic RDT format to be successfully adapted to other disease targets, to see widespread distribution, and to improve clinical outcomes for patients on a global scale, these challenges must be identified and addressed, and the global health community must be engaged in championing the broader use of RDTs.
MIT Department
Massachusetts Institute of Technology. Department of Chemical Engineering
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.5772/61114
